Share Buyback in H. Lundbeck A/S
Acting on its authorization to acquire up to 10% of its shares the H.
Lundbeck Supervisory Board has resolved to initiate a share buyback
program. Under the program H. Lundbeck will buy own shares for an
amount of up to DKK 6 billion, cf. stock exchange announcement number
166 on 17th August 2005.
During any one single trading day a maximum of 25% of the average
daily trading volume of Lundbeck shares on the Copenhagen Stock
Exchange, calculated over 20 days prior to each trading date, will be
bought back, as the share buyback program is implemented in
accordance with the provisions of the European Commission's
regulation no. 2273/2003 of December 22, 2003.
At least once every seven trading days, Lundbeck will issue an
announcement in respect of the transactions made under the program.
The following transactions have been made under the program:
No. of shares Average Transaction value
purchase price (DKK)
(DKK)
Accumulated, last 23,946,542 135.1989 3,237,546,967
announcement
8 November 2007 67,287 140.0409 9,422,929.84
9 November 2007 24,765 142.6225 3,532,045.36
12 November 2007 -- -- --
13 November 2007 -- -- --
14 November 2007 -- -- --
15 November 2007 -- -- --
16 November 2007 103,383 147.3750 15,236,074.34
Accumulated under the 24,141,977 135.2722 3,265,738,364
program
Following the above buyback it is hereby announced that Lundbeck owns
a total of 4,985,190 own shares at a nominal value of DKK 5, equal to
2.41% of the total number of 207,279,631 shares.
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79 +45 36 43 82 62
________________________
Stock Exchange Release No 304 - 16 November 2007
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com